Gastroparesis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

The gastroparesis pipeline consists of 17 pharmaceuticals spanning all stages of development, with approximately 90% of the drugs in early-stage development. Antagonists targeting the D2 receptor are expected to remain an important mechanism of action within the gastroparesis space. The report provides a data-driven overview of the current and future competitive landscape in gastroparesis therapeutics.

Gastroparesis is a chronic disease characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction of the stomach. Patients with gastroparesis experience chronic symptoms with episodes of exacerbation, which typically include postprandial fullness, nausea, vomiting, and upper abdominal pain. Patients may also present with gastroparesis-like symptoms without delayed gastric emptying, complicating the identification of patients with the disease. The overlap of upper gastrointestinal symptoms makes the distinction between gastroparesis and other disorders, such as functional dyspepsia, more challenging.

Gastroparesis is more than twice as common in females as in males. Caucasians have the highest prevalence of any type of gastroparesis across all ages, followed by African Americans. Diabetic gastroparesis patients had a significantly higher risk of mortality than those with idiopathic gastroparesis in the UK. Gastroparesis is largely undiagnosed because many patients with diabetic gastroparesis are asymptomatic.


Who Upvoted this Story


Comments